Updates are available Correction dated 2025-10-23
Click to view Correction: https://doi.org/10.1186/s13058-025-02154-y
-
Authors
Ravani, Lis Victoria
Bagheri, Zahra
Brufsky, Adam M.
Michelon, Isabella
O’Regan, Ruth
Lustberg, Maryam
Han, Hyo
Wang, Ming
Wander, Seth A.
- License Information
-
More Information
Article History
Received: 5 March 2025
Accepted: 25 July 2025
First Online: 13 August 2025
Change Date: 23 October 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13058-025-02154-y
Declarations
:
: Not applicable.
: Not applicable.
: The Authors declare no Competing Non-Financial Interests but the following Competing Financial Interests: AMB – Consulting: Astrazeneca, Pfizer, Novartis, Lilly, Genentech/Roche, Daiichi Sankyo, Merck, Agendia, Sanofi, Puma, Myriad, Gilead, Bria Cell. Research Support: Agendia, Astrazeneca. RO - Advisory Board: Pfizer. HH - Advisory Board: Pfizer, Arvinas. Research Funding: Mersana, Eisai, Ellipses Pharma. Institutional Research Support: Pfizer, Arvinas, Zymeworks, QuantumLeap Health, Department of Defense, Phoenix Pharmaceuticals, Celcuity, Senhwa Biosciences, Pionyr. SAW - Consulting/Advisory Board: Foundation Medicine, Veracyte, Hologic, Eli Lilly, Biovica, Pfizer/Arvinas, Puma Biotechnology, Novartis, AstraZeneca, Genentech, Regor Therapeutics, Menarini, Gilead. Education/Speaking: Eli Lilly, Guardant Health, 2ndMD. Institutional Research Support: Genentech, Eli Lilly, Pfizer/Arvinas, Nuvation Bio, Regor Therapeutics, Sermonix.
